Karen J. Wilson has more than 30 years of industry and leadership experience in life sciences companies across finance, strategy, and risk management. She joined Elicio’s Board in June 2023, after the merger with Angion Biomedica where she had been a board member since April 2020. She also currently serves as independent director and audit committee chair for Connect Biopharma, and LAVA Therapeutics. Ms. Wilson previously served as a board member at Vaxart, Inc. until August 2022. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a pharmaceutical company, until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz in 2011, she served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. She previously served as a principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte & Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant in the State of California and received a B.S. in Business from the University of California, Berkeley.